{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:00:24Z","timestamp":1787029224477,"version":"build-2736575974"},"reference-count":44,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"VegenatHealthcare (Spain)","award":["IFI20\/00034"],"award-info":[{"award-number":["IFI20\/00034"]}]},{"DOI":"10.13039\/501100004587","name":"Carlos III National Health Institute","doi-asserted-by":"publisher","award":["IFI20\/00034"],"award-info":[{"award-number":["IFI20\/00034"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Social Fund Plus","award":["IFI20\/00034"],"award-info":[{"award-number":["IFI20\/00034"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Background: The combination of elexacaftor\u2013tezacaftor\u2013ivacaftor modulators (ETI) has improved clinical outcomes for people with cystic fibrosis (pwCF). Objectives: This study aimed to evaluate changes in nutritional and morphofunctional assessments, as well as anxiety, depression symptoms, and quality of life, in pwCF after starting ETI therapy. Methods: This was a prospective observational study. We measured body composition (fat mass [FM] and fat-free mass [FFM]) using bioelectrical impedance analysis (BIA) and skinfold thickness measurements (SMs). We also assessed hand grip strength, dietary intake via surveys, blood and stool biomarkers, symptoms of anxiety and depression using the Hospital Anxiety and Depression Scale [HADS], and quality of life through the Cystic Fibrosis Questionnaire\u2014Revised (CFQR). Results: A total of 31 pwCF were evaluated. Significant improvements were observed in respiratory function and quality of life, alongside an average weight increase of approximately 5 kg (60% FM and 40% FFM). The prevalence of malnutrition, based on BMI and the FFM index, decreased significantly, while the rate of overweight\/obesity increased. Biomarker analysis indicated better nutrient absorption and reduced intestinal inflammation, as evidenced by significant changes in faecal calprotectin, nitrogen, and fat levels, as well as blood lipid and vitamin profiles. Conclusions: Despite a reduction in caloric intake, an increase in weight was observed one year after initiating ETI. This increase was attributed to gains in both FM and FFM, suggesting improved metabolic efficiency and nutrient absorption. Both SM and BIA were found to be useful assessment tools. These findings indicate the need to modify the nutritional approach, focusing on the quality rather than the quantity of intake, and aiming for an appropriate body composition (FFM) rather than solely focusing on BMI.<\/jats:p>","DOI":"10.3390\/nu16193293","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T04:57:28Z","timestamp":1727672248000},"page":"3293","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Impact of Elexacaftor\u2013Tezacaftor\u2013Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study"],"prefix":"10.3390","volume":"16","author":[{"given":"Francisco","family":"Hevilla","sequence":"first","affiliation":[{"name":"Departamento de Medicina y Dermatolog\u00eda, Facultad de Medicina, University of Malaga, 29010 Malaga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Plataforma Bionand, 29010 Malaga, Spain"},{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Endocrinolog\u00eda y Nutrici\u00f3n, Hospital Regional Universitario de M\u00e1laga, 29007 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0503-9708","authenticated-orcid":false,"given":"Nuria","family":"Porras","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Plataforma Bionand, 29010 Malaga, Spain"},{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Endocrinolog\u00eda y Nutrici\u00f3n, Hospital Regional Universitario de M\u00e1laga, 29007 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9997-5048","authenticated-orcid":false,"given":"Mar\u00eda Victoria","family":"Gir\u00f3n","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Neumolog\u00eda, Hospital Regional Universitario de M\u00e1laga, 29010 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5131-4478","authenticated-orcid":false,"given":"Mar\u00eda","family":"Garc\u00eda-Olivares","sequence":"additional","affiliation":[{"name":"Departamento de Medicina y Dermatolog\u00eda, Facultad de Medicina, University of Malaga, 29010 Malaga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Plataforma Bionand, 29010 Malaga, Spain"},{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Endocrinolog\u00eda y Nutrici\u00f3n, Hospital Regional Universitario de M\u00e1laga, 29007 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Padial","sequence":"additional","affiliation":[{"name":"Departamento de Medicina y Dermatolog\u00eda, Facultad de Medicina, University of Malaga, 29010 Malaga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Plataforma Bionand, 29010 Malaga, Spain"},{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Endocrinolog\u00eda y Nutrici\u00f3n, Hospital Regional Universitario de M\u00e1laga, 29007 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0739-2567","authenticated-orcid":false,"given":"Francisco Jos\u00e9","family":"S\u00e1nchez-Torralvo","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Plataforma Bionand, 29010 Malaga, Spain"},{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Endocrinolog\u00eda y Nutrici\u00f3n, Hospital Regional Universitario de M\u00e1laga, 29007 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-7400","authenticated-orcid":false,"given":"Casilda","family":"Olveira","sequence":"additional","affiliation":[{"name":"Departamento de Medicina y Dermatolog\u00eda, Facultad de Medicina, University of Malaga, 29010 Malaga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Plataforma Bionand, 29010 Malaga, Spain"},{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Neumolog\u00eda, Hospital Regional Universitario de M\u00e1laga, 29010 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7646-2899","authenticated-orcid":false,"given":"Gabriel","family":"Olveira","sequence":"additional","affiliation":[{"name":"Departamento de Medicina y Dermatolog\u00eda, Facultad de Medicina, University of Malaga, 29010 Malaga, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA), Plataforma Bionand, 29010 Malaga, Spain"},{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Endocrinolog\u00eda y Nutrici\u00f3n, Hospital Regional Universitario de M\u00e1laga, 29007 Malaga, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Diabetes y Enfermedades Metab\u00f3licas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"key":"ref_1","first-page":"215","article-title":"Care of People with Cystic Fibrosis: What Is the Role of Specialists in Endocrinology and Nutrition?","volume":"68","year":"2021","journal-title":"Endocrinol. Diabetes Nutr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for the Care of People with Cystic Fibrosis; Establishing and Maintaining Health","volume":"23","author":"Southern","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and Safety of the Elexacaftor plus Tezacaftor plus Ivacaftor Combination Regimen in People with Cystic Fibrosis Homozygous for the F508del Mutation: A Double-Blind, Randomised, Phase 3 Trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.arbres.2023.05.017","article-title":"Experience With Elexacaftor\/Tezacaftor\/Ivacaftor in Patients With Cystic Fibrosis and Advanced Disease","volume":"59","author":"Sole","year":"2023","journal-title":"Arch. Bronconeumol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1513\/AnnalsATS.202312-1065OC","article-title":"Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease","volume":"21","author":"Burgel","year":"2024","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of Elexacaftor-Tezacaftor-Ivacaftor on Body Weight and Metabolic Parameters in Adults with Cystic Fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.clnu.2016.03.004","article-title":"ESPEN-ESPGHAN-ECFS Guidelines on Nutrition Care for Infants, Children, and Adults with Cystic Fibrosis","volume":"35","author":"Turck","year":"2016","journal-title":"Clin. Nutr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1177\/0884533613507086","article-title":"Malnutrition in Cystic Fibrosis: A Review","volume":"28","author":"Culhane","year":"2013","journal-title":"Nutr. Clin. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Westh\u00f6lter, D., Haubold, J., Welsner, M., Salh\u00f6fer, L., Wienker, J., Sutharsan, S., Stra\u00dfburg, S., Taube, C., Umutlu, L., and Schaarschmidt, B.M. (2024). Elexacaftor\/Tezacaftor\/Ivacaftor Influences Body Composition in Adults with Cystic Fibrosis: A Fully Automated CT-Based Analysis. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-59622-2"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","article-title":"ESPEN-ESPGHAN-ECFS Guideline on Nutrition Care for Cystic Fibrosis","volume":"43","author":"Wilschanski","year":"2024","journal-title":"Clin. Nutr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.nut.2018.03.052","article-title":"Cystic Fibrosis, Body Composition, and Health Outcomes: A Systematic Review","volume":"55\u201356","author":"Calella","year":"2018","journal-title":"Nutrition"},{"key":"ref_14","first-page":"376","article-title":"Assessment of Body Composition in Cystic Fibrosis: Agreement between Skinfold Measurement and Densitometry","volume":"39","author":"Olveira","year":"2022","journal-title":"Nutr. Hosp."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-Based Practice Recommendations for Nutrition-Related Management of Children and Adults with Cystic Fibrosis and Pancreatic Insufficiency: Results of a Systematic Review","volume":"108","author":"Stallings","year":"2008","journal-title":"J. Am. Diet. Assoc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101466","DOI":"10.1016\/j.diabet.2023.101466","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Triple Combination Therapy on Glycaemic Control and Body Composition in Patients with Cystic Fibrosis-Related Diabetes","volume":"49","author":"Grancini","year":"2023","journal-title":"Diabetes Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.clnu.2023.10.015","article-title":"A Prospective Study to Assess the Impact of a Novel CFTR Therapy Combination on Body Composition in Patients with Cystic Fibrosis with F508del Mutation","volume":"42","author":"Marazuela","year":"2023","journal-title":"Clin. Nutr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"112425","DOI":"10.1016\/j.nut.2024.112425","article-title":"Impact of CFTR Modulator Therapy on Body Composition as Assessed by Thoracic Computed Tomography: A Follow-up Study","volume":"123","author":"Marazuela","year":"2024","journal-title":"Nutrition"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcf.2023.06.002","article-title":"Weight a Minute: Exploring the Effect on Weight and Body Composition after the Initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in Adults with CF","volume":"22","author":"Proud","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000538606","article-title":"Improved Nutritional Outcomes and Gastrointestinal Symptoms in Adult Cystic Fibrosis Patients Treated with Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"42","author":"Stastna","year":"2024","journal-title":"Dig. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jcf.2023.06.010","article-title":"Body Mass Index and Nutritional Intake Following Elexacaftor\/Tezacaftor\/Ivacaftor Modulator Therapy in Adults with Cystic Fibrosis","volume":"22","author":"Caley","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.genhosppsych.2016.02.002","article-title":"Depression and Anxiety Symptoms in Spanish Adult Patients with Cystic Fibrosis: Associations with Health-Related Quality of Life","volume":"40","author":"Olveira","year":"2016","journal-title":"Gen. Hosp. Psychiatry"},{"key":"ref_23","first-page":"480","article-title":"Body Composition from Fluid Spaces and Density: Analysis of Methods","volume":"9","author":"Siri","year":"1993","journal-title":"Nutrition"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1079\/BJN19740060","article-title":"Body Fat Assessed from Total Body Density and Its Estimation from Skinfold Thickness: Measurements on 481 Men and Women Aged from 16 to 72 Years","volume":"32","author":"Durnin","year":"1974","journal-title":"Br. J. Nutr."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Contreras-Bol\u00edvar, V., Olveira, C., Porras, N., Abu\u00edn-Fern\u00e1ndez, J., Garc\u00eda-Olivares, M., S\u00e1nchez-Torralvo, F.J., Gir\u00f3n, M.V., Ruiz-Garc\u00eda, I., and Olveira, G. (2021). Oral Nutritional Supplements in Adults with Cystic Fibrosis: Effects on Intake, Levels of Fat-Soluble Vitamins, and Bone Remodeling Biomarkers. Nutrients, 13.","DOI":"10.3390\/nu13020669"},{"key":"ref_26","unstructured":"Jimenez, A., and Jim\u00e9nez, A. (2002). Tablas de Composici\u00f3n de Alimentos, Novartis Consumer Health, S.A."},{"key":"ref_27","unstructured":"Mataix, J. (2003). Tablas de Composici\u00f3n de Alimentos Espa\u00f1oles, Universidad de Granada."},{"key":"ref_28","unstructured":"(2024, September 25). Base de Datos BEDCA. Available online: https:\/\/www.bedca.net\/bdpub\/."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.2337\/dc10-0953","article-title":"2010 Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement","volume":"33","author":"Hanas","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1378\/chest.128.4.2347","article-title":"Development and Validation of The Cystic Fibrosis Questionnaire in the United States: A Health-Related Quality-of-Life Measure for Cystic Fibrosis","volume":"128","author":"Quittner","year":"2005","journal-title":"Chest"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0300-2896(01)75101-0","article-title":"Normativa Del Diagn\u00f3stico y El Tratamiento de La Afecci\u00f3n Respiratoria En La Fibrosis Qu\u00edstica","volume":"37","author":"Baranda","year":"2001","journal-title":"Arch. Bronconeumol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/COPD.S121943","article-title":"Predicting High Risk of Exacerbations in Bronchiectasis: The E-FACED Score","volume":"12","author":"Athanazio","year":"2017","journal-title":"Int. J. COPD"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The Hospital Anxiety and Depression Scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.jand.2018.01.013","article-title":"Body Composition Measurement in Bronchiectasis: Comparison between Bioelectrical Impedance Analysis, Skinfold Thickness Measurement, and Dual-Energy X-ray Absorptiometry before and after Pulmonary Rehabilitation","volume":"118","author":"Olveira","year":"2018","journal-title":"J. Acad. Nutr. Diet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nut.2015.10.012","article-title":"Body Composition and Lung Function in Cystic Fibrosis and Their Association with Adiposity and Normal-Weight Obesity","volume":"32","author":"Alvarez","year":"2016","journal-title":"Nutrition"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/ppul.26982","article-title":"Predicting Weight Gain in Patients with Cystic Fibrosis on Triple Combination Modulator","volume":"59","author":"Stewart","year":"2024","journal-title":"Pediatr. Pulmonol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Gruber, W., Stehling, F., Blosch, C., Dillenhoefer, S., Olivier, M., Brinkmann, F., Koerner-Rettberg, C., Sutharsan, S., Mellies, U., and Taube, C. (2024). Longitudinal Changes in Habitual Physical Activity in Adult People with Cystic Fibrosis in the Presence or Absence of Treatment with Elexacaftor\/Tezacaftor\/Ivacaftor. Front. Sport. Act. Living, 6.","DOI":"10.3389\/fspor.2024.1284878"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Philipsen, L.K.D., Olesen, H.V., Jensen, J.H., Olsen, M.F., Faurholt-Jepsen, D., Buchvald, F., Nielsen, K.G., Skov, M., and Pressler, T. (2024). Changes in Exercise Capacity in People with Cystic Fibrosis after One Year of Elexacaftor\/Tezacaftor\/Ivacaftor Treatment\u2014A Danish Prospective Cohort. J. Cyst. Fibros., S1569-1993(24)00055-9.","DOI":"10.1016\/j.jcf.2024.04.010"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Welsner, M., Gruber, W., Blosch, C., Koerner-Rettberg, C., Brinkmann, F., Dillenhoefer, S., Sutharsan, S., Taube, C., Mellies, U., and Olivier, M. (2024). Longitudinal Evaluation of Physical Fitness in Adults with Cystic Fibrosis in the Era of CFTR-Modulating-Therapies. Res. Q. Exerc. Sport, 1\u20139.","DOI":"10.1080\/02701367.2024.2320234"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Stastna, N., Hrabovska, L., Homolka, P., Homola, L., Svoboda, M., Brat, K., and Fila, L. (2024). The Long-Term Effect of Elexacaftor\/Tezacaftor\/Ivacaftor on Cardiorespiratory Fitness in Adolescent Patients with Cystic Fibrosis: A Pilot Observational Study. BMC Pulm. Med., 24.","DOI":"10.1186\/s12890-024-03069-8"},{"key":"ref_41","first-page":"101102","article-title":"Effect of Elexacaftor-Tezacaftor-Ivacaftor on Lipid Parameters in Adults with Cystic Fibrosis: A Single Centre Preliminary Report","volume":"86","author":"Docherty","year":"2024","journal-title":"Respir. Med. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/ppul.26388","article-title":"The Impact of Elexacaftor\/Tezacaftor\/Ivacaftor on Body Composition in a Small Cohort of Youth with Cystic Fibrosis","volume":"58","author":"Granados","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17534666221144211","article-title":"Impact of Elexacaftor\/Tezacaftor\/Ivacaftor on Depression and Anxiety in Cystic Fibrosis","volume":"16","author":"Zhang","year":"2022","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jcf.2023.01.015","article-title":"Suicide Attempts in Adolescents with Cystic Fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor Therapy","volume":"22","author":"Arslan","year":"2023","journal-title":"J. Cyst. Fibros."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/16\/19\/3293\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:06:05Z","timestamp":1760112365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/16\/19\/3293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":44,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["nu16193293"],"URL":"https:\/\/doi.org\/10.3390\/nu16193293","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]}}}